Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma
Tebentafusp (IMCgp100) significantly improved overall survival in HLA-A*02:01-positive advanced uveal melanoma, establishing it as a first-line treatment.
Therapeutic Area
Therapeutic area intelligence for Immune-Mobilizing T-cell Receptors with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.